{'fraction_non_alphanumeric': 0.02040816326530612, 'fraction_numerical': 0.006122448979591836, 'mean_word_length': 6.115942028985507, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intravitreal bevacizumab for macular telangiectasia

Purpose Idiopathic macular telangiectasia Type 2 (idiopathic perifoveolar telangiectasia, ITP) is an uncommon, slowly progressive, usually bilateral disease of the macula, characterized by dilated, tortuous capillaries in the perifoveolar region, preferably in the temporal part. It is the scope of our study to report about a 36 month follow‐up of patients affected by ITP and treated with multiple intravitreal injection of bevacizumab